BioCentury | Mar 19, 2015
Distillery Therapeutics

Therapeutics: Dedicator of cytokinesis 5 (DOCK5)

...help treat osteoporosis. DOCK5 has been implicated in osteoclast activity and bone resorption. In vitro, C21...
...of mouse osteoclasts. In mouse models of osteoporosis, arthritis-related bone loss and metastasis-related bone less, C21...
...with vehicle, without compromising bone-forming processes. Next steps could include in vivo safety testing of C21...
BioCentury | Apr 15, 2013
Clinical News

MethylGene preclinical data

...reduced levels of DNA MeTase and induced expression of an adrenocortical specific gene, steroid hydroxylase (C21...
BioCentury | May 28, 2012
Finance

AbbVie earlier

...splits in two, the firm's head of venture investment, Steven Kuemmerle, said at last week's C21...
BioCentury | May 28, 2012
Finance

Carried away

...Carried away Three out of four corporate VCs on a panel at last week's C21 BioVentures...
BioCentury | Apr 13, 2009
Finance

Ebb & Flow

...the recent Future Leaders in the Biotech Industry conference in New York City and the C21...
...Bernard Sixt. Existing investors will take €15 million ($20.2 million) of that sum. Seeking at C21...
...Hubert Koster, the founder of genomic analysis and diagnostics company Sequenom Inc. (NASDAQ:SQNM), was at C21...
BioCentury | Jul 21, 2008
Finance

Ebb & Flow

...5.3 million shares at $14-$16. The company pulled the offering in February. But at the C21...
BioCentury | May 26, 2008
Finance

Ebb & Flow

...trial funded by the Michael J. Fox Foundation . C'ing green Biotechs at last week's C21...
...cardiovascular disease. Show me the money Among the earlier stage companies looking for financing at C21...
Items per page:
1 - 7 of 7